Dr. Govindan on the Potential for Alectinib

Video

Ramaswamy Govindan, MD, Director, Thoracic Oncology, Co-Director, Section of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential for the ALK inhibitor alectinib.

Ramaswamy Govindan, MD, Director, Thoracic Oncology, Co-Director, Section of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential for the ALK inhibitor alectinib.

Crizotinib and ceritinib are approved in the US and have demonstated 50-60% response rates in patients with ALK-positive non-small cell lung cancer (NSCLC). In a small study in Japan, alectinib elicited a 93% response rate, median survival of 27 months, and activity against brain metastases. Studies in the US are being conducted now comparing crizotinib and alectinib.

There remains a need to understand resistance, and mechanisms of resistance, of these 3 agents. The question also remains as to whether ALK-positive patients should be stratified.

<<<

View more from the 2014 Multidisciplinary Symposium in Thoracic Oncology

Related Videos
Raj Singh, MD
Arya Amini, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology